- Details
- Neeraj Agarwal speaks with Umang Swami about treatment patterns in metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Swami presents encouraging findings from a large retrospective study using the Flatiron Health database of 14,000 patients showing that ADT intensification therapies have risen dramatically from just 40% a few years ago to 77% since January 2023. The data reveals that approx...
|
- Details
- Ashish Kamat hosts Bogdana Schmidt to discuss the evolving landscape of non-muscle invasive bladder cancer treatment. Dr. Schmidt presents a comprehensive overview of risk stratification approaches, highlighting how BCG—despite being the cornerstone treatment for high-risk disease for over 50 years—has significant limitations including side effects, intense treatment schedules, and a 30-40% recurr...
|
- Details
- Zachary Klaassen speaks with Alicia Morgans about examining the impact of PSA doubling time awareness on treatment decisions for high-risk biochemical recurrence. Dr. Morgans discusses findings from a retrospective chart review showing that approximately two-thirds of patients had no documented PSA doubling time, despite it being a crucial risk stratification factor. Among physicians who did docum...
|
- Details
- Alicia Morgans discusses the LEGEND trial with John Taylor, focusing on detalimogene voraplasmid (EG-70) for BCG-refractory non-muscle invasive bladder cancer. Dr. Taylor explains that EG-70 is a non-viral vector drug stimulating both innate and adaptive immune responses through the RIG-I pathway and interleukin 12 enhancement. The phase II trial has enrolled 21 patients in cohort 1 (BCG-refractor...
|
- Details
- Zachary Klaassen hosts Javier Puente to discuss the PARASEC trial. Dr. Puente describes this retrospective observational study examining treatment patterns of patients who received darolutamide in the Spanish cohort of the ARAMIS trial after progression to metastatic castration-resistant prostate cancer (mCRPC). From the 85 evaluable patients, he highlights several key findings: 29% received no fu...
|
- Details
- Neeraj Agarwal speaks with Hannah McManus about research from the IRONMAN registry examining PSA responses and outcomes in metastatic hormone-sensitive prostate cancer patients. Dr. McManus discusses findings from over 1,300 real-world patients across four countries receiving different treatment regimens. The study reveals that patients achieving undetectable PSA nadirs ( 50%) observed in the ADT...
|
- Details
- Zachary Klaassen speaks with Sandip Prasad about the ENVISION trial investigating UGN-102 for primary chemo ablation of recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. Dr. Prasad explains this approach that treats tumors directly rather than using traditional TURBT followed by adjuvant therapy. The trial demonstrates impressive results with a 79.6% complete response rate...
|
- Details
- Oliver Sartor speaks with Alicia Morgans about a long-term study investigating cognitive effects in men with metastatic castration-resistant prostate cancer treated with abiraterone versus enzalutamide. Dr. Morgans discusses how the study evolved from observations made around 2014-2015 regarding potential cognitive impacts of ADT. She outlines the non-randomized trial design which followed patient...
|
- Details
- Alicia Morgans hosts Rana McKay to discuss the PREDICT trial, a biomarker-driven study addressing the unmet need for personalized therapy in advanced prostate cancer. Dr. McKay explains that the trial emerged from a working group seeking to overcome limitations of the NCI-MATCH study for bone-predominant prostate cancer patients. PREDICT enrolls mCRPC patients previously treated with an ARPI and a...
|
- Details
- Ashish Kamat speaks with Lars Dyrskjøt about work from the UROMOL Consortium on comprehensive molecular analysis of non-muscle invasive bladder cancer (NMIBC). Dr. Dyrskjøt describes research incorporating whole exome sequencing, shallow whole genome sequencing, and total RNA sequencing of 438 tumor samples. Their findings reveal distinct genomic landscapes with 33 significantly mutated genes acro...
|
